SUVOREXANT - AN OVERVIEW

nirmatrelvir will increase the stage or outcome of triazolam by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.If unavoidable, watch clients for lack of efficacy Except if usually encouraged during the CYP3A4 substrate prescribing information.Contraindicated (1)nirmatrelvir will increase the amount or influence of triazolam